Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12022837 | 0.83 | CYP3A4 (0.30) | — | |
| SCHEMBL1114588 | 0.83 | CTSL (0.42) | CTSLCTSBGBA1LMNA | |
| SCHEMBL12394743 | 0.82 | LMNA (0.39) | CTSLCTSBLMNA | |
| SCHEMBL12353649 | 0.80 | LMNA (0.43) | LMNA | |
| SCHEMBL1919150 | 0.80 | — | — | |
| SCHEMBL12790596 | 0.80 | CTSL (0.40) | CTSLCTSBGBA1LMNA | |
| SCHEMBL2294201 | 0.80 | CTSL (0.40) | CTSLCTSBGBA1LMNA | |
| SCHEMBL21015663 | 0.78 | LMNA (0.42) | LMNA | |
| SCHEMBL19726464 | 0.78 | — | — | |
| SCHEMBL15112812 | 0.76 | GBA1 (0.32) | CTSLCTSBGBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238461-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | JANSSEN BIOTECH, INC. | 2024-07-18 | — | — | US | disclosed |
| CN-117924548-A | Catalyst component for olefin polymerization, preparation method, catalyst system and olefin polymerization method | 中国石油化工股份有限公司 | 2024-04-26 | — | — | CN | disclosed |
| US-9650456-B2 | Process for producing polydienes | BRIDGESTONE CORPORATION (JP) | 2017-05-16 | — | — | US | disclosed |
| EP-2825574-B1 | PROCESS FOR PRODUCING POLYDIENES | BRIDGESTONE CORP (JP) | 2016-02-24 | — | — | EP | disclosed |
| US-20150031845-A1 | Process For Producing Polydienes | BRIDGESTONE CORPORATION (JP) | 2015-01-29 | — | — | US | disclosed |
| EP-2825574-A1 | PROCESS FOR PRODUCING POLYDIENES | Bridgestone Corporation (JP) | 2015-01-21 | — | — | EP | disclosed |
| CN-104220466-A | Process for producing polydienes | BRIDGESTSONE CORP | 2014-12-17 | — | — | CN | disclosed |
| US-8822688-B2 | Imidazo[1,2-a]pyridine derivative | ASTELLAS PHARMA INC. (JP) | 2014-09-02 | — | — | US | disclosed |
| WO-2013138270-A1 | PROCESS FOR PRODUCING POLYDIENES | BRIDGESTSONE CORPORATION (JP) | 2013-09-19 | — | — | WO | disclosed |
| US-20130053363-A1 | IMIDAZO[1,2-a]PYRIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2013-02-28 | — | — | US | disclosed |
| US-8232246-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2012-07-31 | — | — | US | disclosed |
| US-20100168384-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168384-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | CTSL 730/4885CTSB 275/4885GBA1 817/4885 |
| US-20240238461-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | BDNF, CD47, MAG | CTSL 612/4885CTSB 406/4885GBA1 63/4885 |
| US-20130053363-A1 | IMIDAZO[1,2-a]PYRIDINE DERIVATIVE | PDE4B, PDE4A, PDE4C | CTSL 2717/4885CTSB 1595/4885GBA1 1028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.